TY - JOUR
T1 - Influence of alcohol and acetaldehyde on cognitive function
T2 - findings from an alcohol clamp study in healthy young adults
AU - Ueno, Fumihiko
AU - Matsushita, Sachio
AU - Hara, Sachiko
AU - Oshima, Shunji
AU - Roh, Sungwon
AU - Ramchandani, Vijay A.
AU - Mimura, Masaru
AU - Uchida, Hiroyuki
N1 - Funding Information:
F.U. has received fellowship grants from the Discovery Fund, Nakatani Foundation and the Canadian Institutes of Health Research, and has received consultant fees from VeraSci and Uchiyama Underwriting within the past three years. S.M. has received a research grant from Asahi Breweries and has received speaker's honoraria from EA Pharma, Ono Yakuhin, Otsuka Pharmaceutical and Yoshitomi Yakuhin within the past three years. S.R. has received grants from the Ministry of Health and Welfare, Republic of Korea, Otsuka Pharmaceutical, Janssen Pharmaceutical and Lundbeck and has received the speaker's honoraria from Pfizer within the past three years. M.M. has received grants and/or speaker honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon‐Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji‐Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Tanabe Mitsubishi Pharma and Yoshitomi Yakuhin within the past three years. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon‐Sumitomo Pharma, Mochida Pharmaceutical, Meiji‐Seika Pharmaceutical and Novartis; has received speaker's honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, Dainippon‐Sumitomo Pharma, Meiji‐Seika Pharma, MSD and Janssen Pharmaceutical; and has received advisory panel payments from Dainippon‐Sumitomo Pharma within the past three years. S.H., S.O., and V.A.R. have no competing interests to disclose.
Funding Information:
F.U. has received fellowship grants from the Discovery Fund, Nakatani Foundation and the Canadian Institutes of Health Research, and has received consultant fees from VeraSci and Uchiyama Underwriting within the past three years. S.M. has received a research grant from Asahi Breweries and has received speaker's honoraria from EA Pharma, Ono Yakuhin, Otsuka Pharmaceutical and Yoshitomi Yakuhin within the past three years. S.R. has received grants from the Ministry of Health and Welfare, Republic of Korea, Otsuka Pharmaceutical, Janssen Pharmaceutical and Lundbeck and has received the speaker's honoraria from Pfizer within the past three years. M.M. has received grants and/or speaker honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Tanabe Mitsubishi Pharma and Yoshitomi Yakuhin within the past three years. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical and Novartis; has received speaker's honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD and Janssen Pharmaceutical; and has received advisory panel payments from Dainippon-Sumitomo Pharma within the past three years. S.H., S.O., and V.A.R. have no competing interests to disclose. The authors thank Dr. Motoichiro Kato, a late professor at Keio University School of Medicine, Department of Neuropsychiatry, for advice on the experimental design. We are grateful to Dr. Sean O'Connor at Indiana University School of Medicine and the Indiana Alcohol Research Center (P60 AA 07611) for their support in developing the alcohol clamp technique. This research was supported by Asahi Quality and Innovations. V.A.R. is supported by the NIAAA Division of Intramural Clinical and Biological Research (Z1A AA 000466).
Funding Information:
The authors thank Dr. Motoichiro Kato, a late professor at Keio University School of Medicine, Department of Neuropsychiatry, for advice on the experimental design. We are grateful to Dr. Sean O'Connor at Indiana University School of Medicine and the Indiana Alcohol Research Center (P60 AA 07611) for their support in developing the alcohol clamp technique. This research was supported by Asahi Quality and Innovations. V.A.R. is supported by the NIAAA Division of Intramural Clinical and Biological Research (Z1A AA 000466).
Publisher Copyright:
© 2021 Society for the Study of Addiction
PY - 2022/4
Y1 - 2022/4
N2 - Aims: To investigate the acute effects of intravenous alcohol and its metabolite acetaldehyde on cognitive function in healthy individuals. Design: Experimental pre-test/post-test design. Setting: Kurihama Medical and Addiction Center, Japan. Participants: A total of 298 healthy Japanese people age 20 to 24 years. Measurements: Participants underwent an intravenous alcohol infusion with a target blood alcohol concentration (BAC) of 0.50 mg/mL for 180 minutes. Participants completed the continuous performance test (CPT) for sustained attention, the paced auditory serial addition test (PASAT) for working memory, and the reaction time test (RTT) for speed/accuracy, along with the blood test for BAC and blood acetaldehyde concentration (BAAC) at baseline, 60 and 180 minutes. Findings: Although the target BAC was maintained during the infusion, BAAC peaked at 30 minutes and then gradually declined (η2 = 0.18, P < 0.01). The CPT scores worsened, and the changes between 0 and 60 minutes were correlated with BAAC (correct detection, η2 = 0.09, P < 0.01; r = −0.34, P < 0.01; omission errors, η2 = 0.08, P < 0.01; r = 0.34, P < 0.01). PASAT scores improved through 180 minutes, whereas the changes between 0 and 60 minutes were negatively correlated with BAAC (task one, η2 = 0.02, P < 0.01; r = −0.25, P < 0.01; task two, η2 = 0.03, P < 0.01; r = −0.28, P < 0.01). Although RTTs worsened, they were not associated with BAC or BAAC. None of these comparisons maintained the time effect after controlling for body height. Conclusions: Acetaldehyde exposure following acute intravenous alcohol appears to have a negative impact on sustained attention and working memory, whereas there seems to be only a minor effect of moderate alcohol concentration on speed and accuracy.
AB - Aims: To investigate the acute effects of intravenous alcohol and its metabolite acetaldehyde on cognitive function in healthy individuals. Design: Experimental pre-test/post-test design. Setting: Kurihama Medical and Addiction Center, Japan. Participants: A total of 298 healthy Japanese people age 20 to 24 years. Measurements: Participants underwent an intravenous alcohol infusion with a target blood alcohol concentration (BAC) of 0.50 mg/mL for 180 minutes. Participants completed the continuous performance test (CPT) for sustained attention, the paced auditory serial addition test (PASAT) for working memory, and the reaction time test (RTT) for speed/accuracy, along with the blood test for BAC and blood acetaldehyde concentration (BAAC) at baseline, 60 and 180 minutes. Findings: Although the target BAC was maintained during the infusion, BAAC peaked at 30 minutes and then gradually declined (η2 = 0.18, P < 0.01). The CPT scores worsened, and the changes between 0 and 60 minutes were correlated with BAAC (correct detection, η2 = 0.09, P < 0.01; r = −0.34, P < 0.01; omission errors, η2 = 0.08, P < 0.01; r = 0.34, P < 0.01). PASAT scores improved through 180 minutes, whereas the changes between 0 and 60 minutes were negatively correlated with BAAC (task one, η2 = 0.02, P < 0.01; r = −0.25, P < 0.01; task two, η2 = 0.03, P < 0.01; r = −0.28, P < 0.01). Although RTTs worsened, they were not associated with BAC or BAAC. None of these comparisons maintained the time effect after controlling for body height. Conclusions: Acetaldehyde exposure following acute intravenous alcohol appears to have a negative impact on sustained attention and working memory, whereas there seems to be only a minor effect of moderate alcohol concentration on speed and accuracy.
KW - Acetaldehyde
KW - alcohol
KW - clamp
KW - speed and accuracy
KW - sustained attention
KW - working memory
UR - http://www.scopus.com/inward/record.url?scp=85119599388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119599388&partnerID=8YFLogxK
U2 - 10.1111/add.15733
DO - 10.1111/add.15733
M3 - Article
C2 - 34735038
AN - SCOPUS:85119599388
SN - 0965-2140
VL - 117
SP - 934
EP - 945
JO - Addiction
JF - Addiction
IS - 4
ER -